We systematically reviewed and meta-analyze the efficacy of universal prophylaxis (UP) and
preemptive (PE) strategies (using ganciclovir or valganciclovir) in preventing …

A cytomegalovirus (CMV) donor positive/recipient negative liver transplant recipient
developed CMV syndrome with presumed colitis 2 weeks after discontinuing the standard 3 …

There are no detailed studies on the prevalence or clinical magnitude of bloodstream
infection (BSI) following living donor liver transplantation (LDLT). The study aimed to assess …

AIM: To investigate the incidence and risk factors of late-onset acute rejection (LAR) and to
clarify the effectiveness of our immunosuppressive regime consisting of life-long …

T‐cell depletion is an essential aspect of clinical immunosuppression. The aim of the
present study was to compare the efficacy of two dosage regimens in this setting. We …

Hemophagocytic syndrome is a fatal complication after liver transplantation that is rarely
reported. Among 260 adult patients who underwent living donor liver transplantation at our …

In living donor liver transplantation (LDLT) for primary biliary cirrhosis (PBC), the majority of
donors are genetically related to their recipients, leading to concerns of an earlier …

Post-transplant lymphoproliferative disorder (PTLD) is a serious complication of solid organ
transplant. Although living donor liver transplant (LDLT) has been increasingly performed …

Background Interleukin-2 receptor antagonists (IL2Ra) are used mainly for (1) induction as
an adjunct to conventional immunosuppression,(2) induction to facilitate calcineurin inhibitor …

Thrombotic microangiopathy (TMA) after liver transplantation is thought to be a rare event.
We report a case of TMA after living donor liver transplantation for hepatitis C virus-related …